# ImmunoBlue

Source: https://onco.cc/companies/immunoblue/  
OnCo record `immunoblue` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ImmunoBlue is a Baltimore company that combines nanoparticles with immunotherapy to treat cancer, including a project to make T cells that recognise glioblastoma.

## Summary

ImmunoBlue, LLC, of Baltimore, founded by its chief executive Rohan Fernandes, engineers nanoimmunotherapies that combine nanotechnology and immunotherapy to treat several types of cancer. In fiscal year 2026 the National Cancer Institute funded its STTR project on engineering glioblastoma-specific T cells using immunostimulatory photothermal nanoparticles (5R42CA287488-03, USD 1,106,515).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: IMMUNOBLUE, LLC
- HQ: Baltimore, MD
- Type: biotech
- Website: https://www.immunoblue.com/

## Notes

- Read on immunoblue.com and the NIH RePORTER record on 4 November 2026. The site names no product.

## Sources

- Official website: https://www.immunoblue.com/
- NIH RePORTER: 5R42CA287488-03: https://reporter.nih.gov/project-details/11415186

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Magnetic nanoparticle hyperthermia](https://onco.cc/technologies/magnetic-nanoparticle-hyperthermia/), [Photothermal (plasmonic) nanoparticle ablation](https://onco.cc/technologies/photothermal-nanoparticles/)

---
JSON: https://onco.cc/api/v1/entities/immunoblue.json